Human CellExp™ Recombinant Ebolavirus BDBV Small/secreted Glycoprotein (sGP)
Ebola sGP, Ebolavirus BDBV (subtype Bundibugyo,strain Uganda 2007)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | B8XCN1 |
---|---|
Calculated MW | 34.3 kDa |
Other Names | Ebola sGP, Ebolavirus BDBV (subtype Bundibugyo, strain Uganda 2007) |
---|---|
Gene Source | Bundibugyo virus |
Source | HEK 293 cells |
Assay&Purity | SDS-PAGE;> 95% |
Recombinant | Yes |
Target/Specificity | GP |
Application Notes | Reconstitute in 1X PBS to the desired protein concentration. |
Format | Lyophilized |
Storage | -20°C;Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator(VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDasecreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an importantrole in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, whichare generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 isresponsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrierdecreasing effects of TNF alpha.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.